Mironid extends Series A funding to £35M to develop treatment for ADPKD. Mironid, a Glasgow-based biopharmaceutical company developing small molecule therapeutics, has extended its Series A funding round to £35 million. The round was led by Roche Venture Fund, with participation from existing investors Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, the University of Strathclyde, Scottish Enterprise, and the European Investment Fund.
Mironid will use the funds to progress its lead discovery program through IND-enabling studies and to extend its patent estate. The company is developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease, with a focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is characterized by the growth of fluid-filled cysts in the kidneys and is the most common hereditary kidney disorder. There are currently limited treatment options for ADPKD.
Mironid's lead program is for LoAc®, a small molecule that targets the abnormally high kidney cAMP levels that drive cyst formation. LoAc® has shown promising results in preclinical studies and is currently in IND-enabling studies. Mironid is led by CEO Neil Wilkie. The company has a strong team of experienced scientists and drug developers. This funding round is a significant milestone for Mironid and will help the company advance its development program for LoAc®. The company is well-positioned to make a significant impact in the treatment of ADPKD and other life-threatening hereditary kidney diseases.
